NZ515202A - Method for detecting and killing epithelial cancer cells - Google Patents
Method for detecting and killing epithelial cancer cellsInfo
- Publication number
- NZ515202A NZ515202A NZ515202A NZ51520201A NZ515202A NZ 515202 A NZ515202 A NZ 515202A NZ 515202 A NZ515202 A NZ 515202A NZ 51520201 A NZ51520201 A NZ 51520201A NZ 515202 A NZ515202 A NZ 515202A
- Authority
- NZ
- New Zealand
- Prior art keywords
- marking agent
- mitochondrial
- agent
- cells
- cationic
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims description 19
- 230000002147 killing effect Effects 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 94
- 239000003550 marker Substances 0.000 claims abstract description 71
- 125000002091 cationic group Chemical group 0.000 claims abstract description 46
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 37
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 36
- 210000003470 mitochondria Anatomy 0.000 claims abstract description 33
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims abstract description 16
- 210000000981 epithelium Anatomy 0.000 claims abstract description 11
- 230000014759 maintenance of location Effects 0.000 claims abstract description 11
- 238000001727 in vivo Methods 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 35
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 210000002919 epithelial cell Anatomy 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000007246 mechanism Effects 0.000 claims description 9
- 229940044683 chemotherapy drug Drugs 0.000 claims description 8
- 210000001700 mitochondrial membrane Anatomy 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 231100000419 toxicity Toxicity 0.000 claims description 4
- 230000001988 toxicity Effects 0.000 claims description 4
- 108020005196 Mitochondrial DNA Proteins 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 abstract description 2
- 239000000975 dye Substances 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 12
- 229950003937 tolonium Drugs 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 230000005880 cancer cell killing Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000001016 thiazine dye Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 230000025608 mitochondrion localization Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- IOFXEUZPIIUQAG-UHFFFAOYSA-M Tiemonium iodide Chemical compound [I-].C=1C=CSC=1C(O)(C=1C=CC=CC=1)CC[N+]1(C)CCOCC1 IOFXEUZPIIUQAG-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- SRAVWPVICTXESG-UHFFFAOYSA-N [4-(2,4-diamino-5-methylphenyl)iminocyclohexa-2,5-dien-1-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].C1=C(N)C(C)=CC(N=C2C=CC(C=C2)=[N+](C)C)=C1N SRAVWPVICTXESG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229950008849 furazolium chloride Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- FMPJXUZSXKJUQI-UHFFFAOYSA-N hydron;3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;chloride Chemical compound Cl.O1C([N+](=O)[O-])=CC=C1C1=CSC2=NCCN12 FMPJXUZSXKJUQI-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RNUAEUWXRHCGKX-UHFFFAOYSA-N oxythiamine chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)NC1=O RNUAEUWXRHCGKX-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- XFDQJKDGGOEYPI-UHFFFAOYSA-O peonidin Chemical compound C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 XFDQJKDGGOEYPI-UHFFFAOYSA-O 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- SOUHUMACVWVDME-UHFFFAOYSA-N safranin O Chemical compound [Cl-].C12=CC(N)=CC=C2N=C2C=CC(N)=CC2=[N+]1C1=CC=CC=C1 SOUHUMACVWVDME-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 229960005128 tiemonium iodide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/005387 WO2001064110A1 (en) | 2000-02-28 | 2000-02-28 | Method for detecting and killing epithelial cancer cells |
| PCT/US2001/006318 WO2001064255A1 (en) | 2000-02-28 | 2001-02-27 | Method for detecting and killing epithelial cancer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ515202A true NZ515202A (en) | 2003-05-30 |
Family
ID=21741108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ515202A NZ515202A (en) | 2000-02-28 | 2001-02-27 | Method for detecting and killing epithelial cancer cells |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1214101A4 (es) |
| JP (1) | JP2003525044A (es) |
| KR (2) | KR100907122B1 (es) |
| CN (1) | CN100544770C (es) |
| AU (2) | AU2000237154A1 (es) |
| BR (1) | BR0104747A (es) |
| CA (1) | CA2370741A1 (es) |
| CZ (1) | CZ20013861A3 (es) |
| IL (1) | IL146141A0 (es) |
| MX (1) | MXPA01010886A (es) |
| NO (1) | NO20015242L (es) |
| NZ (1) | NZ515202A (es) |
| RU (1) | RU2226404C2 (es) |
| WO (2) | WO2001064110A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000237154A1 (en) * | 2000-02-28 | 2001-09-12 | Zila, Inc. | Method for detecting and killing epithelial cancer cells |
| EP1294408A4 (en) * | 2000-06-30 | 2005-01-05 | Zila Inc | DIAGNOSTIC AGENT BASED ON RHODAMINE AND METHODS FOR DETECTING EPITHELIAL CANCER |
| AU776256B2 (en) * | 2000-09-26 | 2004-09-02 | Zila Biotechnology, Inc. | Method for early prediction of the onset of invasive cancer |
| EP1463838A4 (en) * | 2001-12-14 | 2006-06-07 | Zila Inc | MOLECULAR ANALYSIS MADE BY DYE FOR THE PROGNOSIS AND DIAGNOSIS OF CANCER |
| US7081261B2 (en) * | 2002-05-14 | 2006-07-25 | National Starch And Chemical Investment Holding Corporation | Resistant starch prepared by isoamylase debranching of low amylose starch |
| US6929817B2 (en) | 2002-05-14 | 2005-08-16 | National Starch & Chemical Investment Holding Corporation | Slowly digestible starch product |
| US6890571B2 (en) | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
| AU2002312319A1 (en) * | 2002-06-04 | 2003-12-22 | Zila Biotechnology, Inc. | Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues |
| MX2007003777A (es) * | 2004-09-30 | 2007-05-24 | Zila Biotechnology Inc | Metodo de luz dirigida para detectar y ayudar en la evaluacon adicional de tejido mucoso anormal. |
| WO2006072625A2 (en) | 2005-01-06 | 2006-07-13 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| US20120178674A1 (en) | 2009-07-15 | 2012-07-12 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
| CN105510321A (zh) * | 2011-12-29 | 2016-04-20 | 闫文广 | 用于上皮组织肿瘤细胞的检测剂组合物及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4321251A (en) * | 1979-12-19 | 1982-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of malignant lesions of the oral cavity utilizing toluidine blue rinse |
| US5194373A (en) * | 1985-06-06 | 1993-03-16 | Thomas Jefferson University | Method of determining endothelial cell coverage of a prosthetic surface |
| US4816395A (en) * | 1985-12-19 | 1989-03-28 | Peralta Cancer Research Institute | Method for predicting chemosensitivity of anti-cancer drugs |
| DK0565668T3 (da) * | 1991-10-31 | 2000-01-31 | Zila Inc | Biologisk farvemiddelsammensætning, fremgangsmåde til fremstilling deraf og til anvendelse til aftegning af epitelcancer |
| KR100342342B1 (ko) * | 1996-01-16 | 2002-08-22 | 자일러, 인코포레이티드 | 구강암및전암성질환의체내검출을위한방법및조성물 |
| US6086852A (en) * | 1997-11-13 | 2000-07-11 | Zila, Inc. | In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
| CN1346282A (zh) * | 1998-12-23 | 2002-04-24 | G.D.西尔公司 | 在肿瘤的治疗中使用环加氧酶－2－抑制剂与一种或多种抗肿瘤剂作为联合治疗的方法 |
| AU2000237154A1 (en) * | 2000-02-28 | 2001-09-12 | Zila, Inc. | Method for detecting and killing epithelial cancer cells |
| AU785490B2 (en) * | 2000-07-20 | 2007-11-15 | Zila Biotechnology, Inc. | Improved diagnostic method for detecting dysplastic epithelial tissue |
| AU776256B2 (en) * | 2000-09-26 | 2004-09-02 | Zila Biotechnology, Inc. | Method for early prediction of the onset of invasive cancer |
-
2000
- 2000-02-28 AU AU2000237154A patent/AU2000237154A1/en not_active Abandoned
- 2000-02-28 WO PCT/US2000/005387 patent/WO2001064110A1/en active Application Filing
-
2001
- 2001-02-27 RU RU2001132076/15A patent/RU2226404C2/ru not_active IP Right Cessation
- 2001-02-27 AU AU43316/01A patent/AU785489B2/en not_active Ceased
- 2001-02-27 EP EP01916271A patent/EP1214101A4/en not_active Ceased
- 2001-02-27 MX MXPA01010886A patent/MXPA01010886A/es active IP Right Grant
- 2001-02-27 IL IL14614101A patent/IL146141A0/xx unknown
- 2001-02-27 CZ CZ20013861A patent/CZ20013861A3/cs unknown
- 2001-02-27 NZ NZ515202A patent/NZ515202A/en unknown
- 2001-02-27 KR KR1020017013731A patent/KR100907122B1/ko not_active IP Right Cessation
- 2001-02-27 CA CA002370741A patent/CA2370741A1/en not_active Abandoned
- 2001-02-27 WO PCT/US2001/006318 patent/WO2001064255A1/en active Application Filing
- 2001-02-27 BR BR0104747-7A patent/BR0104747A/pt not_active Application Discontinuation
- 2001-02-27 JP JP2001563152A patent/JP2003525044A/ja active Pending
- 2001-02-27 CN CNB018006604A patent/CN100544770C/zh not_active Expired - Fee Related
- 2001-02-27 KR KR1020087020377A patent/KR20080080681A/ko not_active Application Discontinuation
- 2001-10-26 NO NO20015242A patent/NO20015242L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL146141A0 (en) | 2002-07-25 |
| KR20080080681A (ko) | 2008-09-04 |
| AU785489B2 (en) | 2007-11-15 |
| RU2226404C2 (ru) | 2004-04-10 |
| CA2370741A1 (en) | 2001-09-07 |
| NO20015242D0 (no) | 2001-10-26 |
| EP1214101A4 (en) | 2005-04-13 |
| JP2003525044A (ja) | 2003-08-26 |
| CN1365288A (zh) | 2002-08-21 |
| KR20020000222A (ko) | 2002-01-05 |
| WO2001064255A1 (en) | 2001-09-07 |
| EP1214101A1 (en) | 2002-06-19 |
| WO2001064110A1 (en) | 2001-09-07 |
| AU2000237154A1 (en) | 2001-09-12 |
| CZ20013861A3 (cs) | 2002-08-14 |
| MXPA01010886A (es) | 2002-05-06 |
| NO20015242L (no) | 2001-11-29 |
| KR100907122B1 (ko) | 2009-07-09 |
| AU4331601A (en) | 2001-09-12 |
| CN100544770C (zh) | 2009-09-30 |
| BR0104747A (pt) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6756063B2 (en) | Methods and compositions for the treatment of human and animal cancers | |
| AU785489B2 (en) | Method for detecting and killing epithelial cancer cells | |
| Muscella et al. | [Pt (O, O′‐acac)(γ‐acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF‐7 breast cancer cells via the mitochondrial apoptotic pathway | |
| KR20140136525A (ko) | 암 치료를 위한 화합물 및 방법 | |
| JP2007508384A (ja) | 癌を処置するための方法および組成物 | |
| Duan et al. | Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells | |
| EP2890374B1 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
| Chan et al. | Photodynamic activity of a glucoconjugated silicon (IV) phthalocyanine on human colon adenocarcinoma | |
| US6649144B1 (en) | Method for detecting and killing epithelial cancer cells | |
| US20030017158A1 (en) | Method for detecting and killing epithelial cancer cells | |
| Wang et al. | Transethosome‐Based Topical Administration Systems with Enhanced Penetration and Dual Actions for Treating EGFR‐Overexpressed Cutaneous Squamous Cell Carcinoma | |
| Durante et al. | In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin | |
| RU2713151C1 (ru) | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения | |
| Wang et al. | Branched α-helical peptides enhanced antitumor efficacy and selectivity | |
| Varmazyad et al. | N-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced cancer versus normal cell toxicity | |
| BRPI0612367A2 (pt) | solução para a marcação de células ou de tecidos, kit, método de marcação ex vivo de células ou de um tecido, uso de uma solução e método de diagnóstico in vitro de um cáncer ou de uma displasia | |
| PL229503B1 (pl) | Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów | |
| Miyagi et al. | Crystal violet combined with Merocyanine 540 for the ex vivo purging of hematopoietic stem cell grafts | |
| US20110077230A1 (en) | Copper organocomplexes, use thereof as antitumor means and for protecting healthy tissue from ionizing radiation | |
| CN115444941B (zh) | pH响应释药的双药纳米钻石药物及其制备方法和应用 | |
| WO2014090586A1 (de) | Delphinidin zur bekämpfung von melanomzellen | |
| Kosova et al. | Anticancer effects of a newly-synthesized benzoxazole-derived 5-amino-2-[P-bromophenyl]-benzoxazole in breast cancer cell lines | |
| Schmid et al. | Differential uptake of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea and doxorubicin by Lewis lung carcinoma and Ridgway osteogenic sarcoma | |
| CN114685641A (zh) | 一种抑制brca1/bard1复合体结合的多肽及其应用和防治癌症的药物 | |
| Drewa et al. | Influence of a novel platinum compound—cisdichloro (dimethylsulphoxide)(1-β-D-ribofuranosyl-1, 2, 4-triazolo-3-carboxyamide) platinum (II)—“Pt-rib-1”—on cell cycle and apoptosis in CLS91 and B16 mouse melanoma in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: ZILA BIOTECHNOLOGY, INC., US Free format text: OLD OWNER(S): ZILA, INC. |
|
| RENW | Renewal (renewal fees accepted) |